- 現金殖利率: 4.96%、總殖利率: 4.96%、5年平均現金配發率: 97.92%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 (5) | 1.05 | 56.72 | 1.22 | 52.5 | 0.00 | 0 | 116.19 | -2.69 | 0.00 | 0 | 116.19 | -2.69 |
| 2024 (4) | 0.67 | -94.99 | 0.80 | -91.39 | 0.00 | 0 | 119.40 | 71.84 | 0.00 | 0 | 119.40 | 25.01 |
| 2023 (3) | 13.37 | 20.89 | 9.29 | -6.16 | 3.48 | 0 | 69.48 | -22.37 | 26.03 | 0 | 95.51 | 6.7 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 26Q1 (8) | 0.29 | -9.38 | -21.62 | 0.01 | -96.15 | -87.5 | 0.29 | -72.38 | -21.62 |
| 25Q4 (7) | 0.32 | 68.42 | 39.13 | 0.26 | 30.0 | -29.73 | 1.05 | 45.83 | 56.72 |
| 25Q3 (6) | 0.19 | 18.75 | -90.31 | 0.20 | -13.04 | 17.65 | 0.72 | 35.85 | -83.78 |
| 25Q2 (5) | 0.16 | -56.76 | -94.68 | 0.23 | 187.5 | 27.78 | 0.53 | 43.24 | -84.13 |
| 25Q1 (4) | 0.37 | 60.87 | 0.0 | 0.08 | -78.38 | 0.0 | 0.37 | -44.78 | 0.0 |
| 24Q4 (3) | 0.23 | -88.27 | 0.0 | 0.37 | 117.65 | 0.0 | 0.67 | -84.91 | 0.0 |
| 24Q3 (2) | 1.96 | -34.88 | 0.0 | 0.17 | -5.56 | 0.0 | 4.44 | 32.93 | 0.0 |
| 24Q2 (1) | 3.01 | 0.0 | 0.0 | 0.18 | 0.0 | 0.0 | 3.34 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 2.24 | -8.18 | 18.23 | 8.53 | 17.3 | 6.58 | N/A | - | ||
| 2026/3 | 2.44 | 28.93 | 19.71 | 6.29 | 16.97 | 6.29 | 0.68 | - | ||
| 2026/2 | 1.89 | -3.04 | 6.32 | 3.85 | 15.29 | 6.28 | 0.68 | - | ||
| 2026/1 | 1.95 | -19.56 | 25.57 | 1.95 | 25.57 | 8.29 | 0.52 | - | ||
| 2025/12 | 2.43 | -37.85 | 14.26 | 26.33 | 18.0 | 8.25 | 0.5 | - | ||
| 2025/11 | 3.91 | 104.61 | 8.99 | 23.9 | 18.39 | 7.88 | 0.53 | - | ||
| 2025/10 | 1.91 | -7.49 | 0.13 | 19.99 | 20.42 | 6.04 | 0.69 | - | ||
| 2025/9 | 2.06 | -0.15 | 14.54 | 18.08 | 23.06 | 6.23 | 0.64 | - | ||
| 2025/8 | 2.07 | -1.29 | 16.53 | 16.02 | 24.25 | 6.54 | 0.61 | - | ||
| 2025/7 | 2.09 | -11.86 | 31.03 | 13.95 | 25.48 | 6.68 | 0.6 | - | ||
| 2025/6 | 2.38 | 7.7 | 47.75 | 11.86 | 24.55 | 6.48 | 0.5 | - | ||
| 2025/5 | 2.21 | 16.36 | 33.49 | 9.48 | 19.83 | 6.14 | 0.53 | - | ||
| 2025/4 | 1.9 | -7.02 | 8.96 | 7.27 | 16.23 | 5.72 | 0.57 | - | ||
| 2025/3 | 2.04 | 14.5 | 76.4 | 5.38 | 19.03 | 5.38 | 0.52 | 因為子公司大研生醫去年3月業績有一次性因素導致基期較低，所以今年3月YoY較高，主要是基期較低因素導致 | ||
| 2025/2 | 1.78 | 14.51 | 10.02 | 3.34 | -0.7 | 5.46 | 0.51 | - | ||
| 2025/1 | 1.56 | -26.8 | -10.68 | 1.56 | -10.68 | 7.27 | 0.39 | - | ||
| 2024/12 | 2.13 | -40.71 | 19.26 | 22.31 | 7.54 | 7.62 | 0.32 | - | ||
| 2024/11 | 3.58 | 87.96 | 25.66 | 20.18 | 6.44 | 7.29 | 0.34 | - | ||
| 2024/10 | 1.91 | 5.82 | 0.53 | 16.6 | 3.04 | 5.48 | 0.45 | - | ||
| 2024/9 | 1.8 | 1.57 | 8.33 | 14.69 | 3.37 | 5.17 | 0.6 | - | ||
| 2024/8 | 1.77 | 10.99 | 0.58 | 12.89 | 2.72 | 4.98 | 0.63 | - | ||
| 2024/7 | 1.6 | -0.61 | 4.35 | 11.12 | 3.07 | 4.86 | 0.64 | - | ||
| 2024/6 | 1.61 | -2.69 | 2.21 | 9.52 | 2.86 | 5.0 | 0.56 | - | ||
| 2024/5 | 1.65 | -5.02 | -1.71 | 7.91 | 2.99 | 5.07 | 0.56 | - | ||
| 2024/4 | 1.74 | 50.51 | 15.71 | 6.26 | 4.31 | 5.04 | 0.56 | - | ||
| 2024/3 | 1.68 | 3.57 | 5.56 | 5.04 | 12.08 | 5.04 | N/A | - | ||
| 2024/2 | 1.62 | -7.04 | 11.14 | 3.36 | 15.64 | 5.14 | N/A | - | ||
| 2024/1 | 1.74 | -2.26 | 20.17 | 1.74 | 20.17 | 6.38 | N/A | - | ||
| 2023/12 | 1.78 | -37.53 | 16.7 | 20.74 | 13.04 | 6.53 | N/A | - | ||
| 2023/11 | 2.85 | 50.37 | 31.6 | 18.96 | 12.71 | 6.41 | N/A | - | ||
| 2023/10 | 1.9 | 14.03 | 29.57 | 16.11 | 9.91 | 5.32 | N/A | - | ||
| 2023/9 | 1.66 | -5.68 | 20.59 | 14.21 | 7.73 | 4.96 | N/A | - | ||
| 2023/8 | 1.76 | 15.15 | 23.32 | 12.55 | 6.23 | 4.87 | N/A | - | ||
| 2023/7 | 1.53 | -2.65 | 5.47 | 10.79 | 3.88 | 4.79 | N/A | - | ||
| 2023/6 | 1.57 | -6.43 | -0.9 | 9.25 | 3.62 | 4.76 | N/A | - | ||
| 2023/5 | 1.68 | 11.82 | 4.92 | 7.68 | 4.6 | 4.77 | N/A | - | ||
| 2023/4 | 1.5 | -5.32 | 6.14 | 6.0 | 4.51 | 4.55 | N/A | - | ||
| 2023/3 | 1.59 | 9.05 | 11.21 | 4.49 | 3.97 | 4.49 | N/A | - | ||
| 2023/2 | 1.46 | 0.51 | 6.55 | 2.91 | 0.4 | 4.43 | N/A | - | ||
| 2023/1 | 1.45 | -5.09 | -5.1 | 1.45 | -5.1 | 5.14 | N/A | - | ||
| 2022/12 | 1.53 | -29.55 | -7.3 | 18.35 | 11.42 | 5.16 | N/A | - | ||
| 2022/11 | 2.17 | 48.06 | 22.33 | 16.82 | 13.5 | 5.01 | N/A | - | ||
| 2022/10 | 1.46 | 6.12 | 0.2 | 14.66 | 12.3 | 4.27 | N/A | - | ||
| 2022/9 | 1.38 | -3.54 | -0.02 | 13.19 | 13.82 | 4.26 | N/A | - | ||
| 2022/8 | 1.43 | -1.51 | 0.89 | 11.81 | 15.69 | 4.47 | N/A | - | ||
| 2022/7 | 1.45 | -8.53 | 3.96 | 10.38 | 18.08 | 4.64 | N/A | - | ||
| 2022/6 | 1.59 | -0.94 | 10.96 | 8.93 | 20.75 | 4.61 | N/A | - | ||
| 2022/5 | 1.6 | 13.12 | 16.11 | 7.34 | 23.1 | 4.45 | N/A | - | ||
| 2022/4 | 1.42 | -0.8 | 21.58 | 5.74 | 25.2 | 4.21 | N/A | - | ||
| 2022/3 | 1.43 | 4.47 | 20.18 | 4.32 | 26.43 | 4.32 | N/A | - | ||
| 2022/2 | 1.37 | -10.48 | 24.09 | 2.89 | 29.77 | 4.54 | N/A | - | ||
| 2022/1 | 1.53 | -7.28 | 35.31 | 1.53 | 35.31 | 4.95 | N/A | - | ||
| 2021/12 | 1.65 | -7.03 | 35.69 | 16.47 | 60.06 | 4.88 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有累計虧損，長期來看需謹慎觀察 | ||
| 2021/11 | 1.77 | 21.27 | 53.37 | 14.82 | 63.32 | 4.61 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有累計虧損，長期來看需謹慎觀察 | ||
| 2021/10 | 1.46 | 5.88 | 87.53 | 13.05 | 64.77 | 4.26 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/9 | 1.38 | -2.65 | 67.03 | 11.59 | 62.29 | 4.19 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/8 | 1.42 | 1.48 | 81.09 | 10.21 | 61.67 | 4.25 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/7 | 1.4 | -2.38 | 74.18 | 8.79 | 58.92 | 4.21 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/6 | 1.43 | 3.65 | 72.55 | 7.4 | 56.34 | 0.0 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 | ||
| 2021/5 | 1.38 | 18.46 | 68.72 | 5.96 | 52.89 | 0.0 | N/A | 因直播成長與大研生醫熱銷，惟大研採用國際頂級臨床醫學實證原料與研發專利配方成本頗高，尚有大額累計虧損，長期來看需謹慎觀察 |